The Quest for Justice by OM Investors
LOS ANGELES, Sept. 6, 2024 — Investors in Outset Medical, Inc. have a potentially groundbreaking opportunity to pursue a securities fraud class action lawsuit against the Company (NASDAQ: OM).
Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024
If you have suffered financial setbacks as a shareholder, a door has opened for your involvement.
The lawsuit asserts that over the specified period, the Defendants neglected to disclose crucial information to investors. These concealed facts include the unauthorized marketing of Tablo products for continuous renal replacement therapy, a notable omission considering FDA approval was not obtained for such use. Additionally, the Company’s failure to communicate the likelihood of submitting an additional 510(k) application for the Tablo products indicates a lack of transparency. Furthermore, the risk of halting sales due to pending FDA approval, deficiencies in the sales team and process for Tablo products, and the subsequent adverse impact on revenue growth were not shared. The net effect was a misrepresentation of Outset Medical’s business operations and prospects, causing a ripple of misleading positivity.
Stay updated by following us on Twitter at twitter.com/FRC_LAW.
If you wish to delve further into this legal battle or seek clarification on your rights regarding this class action, reach out to Frank R. Cruz of The Law Offices of Frank R. Cruz in Century City, California at 310-914-5007, email info@frankcruzlaw.com, or visit the website at www.frankcruzlaw.com. Ensure to provide essential contact details if inquiring via email.
Note: In certain jurisdictions, this press release may be considered Attorney Advertising based on applicable legal and ethical standards.
View original content to download multimedia: https://www.prnewswire.com/news-releases/om-investors-have-opportunity-to-lead-outset-medical-inc-securities-fraud-lawsuit-302241061.html